Canopy Growth Corporation (CGC)

Environment story

The 10-K contains no disclosure of Scope 1, 2, or 3 greenhouse gas emissions, no stated net-zero target year, and no quantified renewable-electricity percentage. Under the deterministic rubric, the absence of Scope 3 disclosure and the absence of a net-zero commitment before 2045 each trigger a 15-point deduction. No verifiable, sourced environmental controversy (e.g., toxic waste, water-use disputes) appears in the filing, so no additional controversy deduction was applied. No physical decarbonization infrastructure investments are disclosed, so no offsetting credit was applied. This is an informational research assessment based solely on filed disclosures and is not investment advice.

Social story

The 10-K does not disclose CEO-to-median-worker pay ratio, workforce diversity percentages, turnover rates, or union relationship status, and does not describe supply-chain human-rights audits (the company's inputs are agricultural cannabis and device manufacturing, not conflict-mineral-linked). No documented union suppression activity, strikes, or supply-chain labor-rights violations were found in the filing. Under the rubric, absent verified negative facts, no deductions were applied. This reflects an analytical reading of disclosed material only and is not a personalized investment recommendation.

Governance story

Canopy Growth disclosed a material weakness in internal control over financial reporting as of March 31, 2026, resulting in a restatement of previously issued financial statements for fiscal years 2024-2026, and management concluded disclosure controls were not effective. The company is also subject to an active regulatory investigation and inquiry connected to its self-reported BioSteel Review. These constitute significant, verifiable regulatory/financial-reporting proceedings, triggering the maximum 20-point deduction under the antitrust/consumer-safety/financial-fraud proceedings category. No dual-class founder supermajority voting structure was identified (Canopy Shares are the company's common equity; Exchangeable and Non-Voting Shares relate to the Canopy USA holding structure rather than concentrated founder control), so no deduction was applied there. Board independence percentage was not disclosed in the reviewed material. No lobbying activity targeting climate or consumer-protection rollback was disclosed. This assessment is descriptive research output and does not constitute financial advice.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Canopy Growth Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Canopy Growth Corporation in the app for interactive charts and portfolio building.

More in Healthcare